When does Nicoderm CQ (nicotine transdermal system) lose Orange Book-listed patent protection?
FDA’s Orange Book tracks approved drug products and, separately, patent and exclusivity records tied to those products. For Nicoderm CQ, the specific “expiration” date depends on which Orange Book-listed patent(s) are attached to the exact labeled drug (including strength and manufacturer). The FDA Orange Book does not provide one single universal date for a whole category of products; it shows each listed patent with its own expiration/“deemed” dates.
To get the precise expiration(s) for the Nicoderm CQ “nicotine transdermal system” entry you care about, you need to look up the relevant Orange Book record and read the “Patents” section for each listed patent and its listed expiration date.
How to find the exact Orange Book patent expiration date for Nicoderm CQ
Search the FDA Orange Book for:
1) “Nicoderm CQ”
2) the active ingredient “nicotine”
3) the dosage form “transdermal system” (and the matching strength, if listed separately)
Then open the “Patents” details. Orange Book records typically list:
- Patent number(s)
- Patentee/applicant
- Patent expiration date
- Patent type (for example, drug substance, drug product, or method-of-use, where applicable)
That expiration date is what matters for whether another product can rely on the same patent framework (subject to regulatory and litigation outcomes).
Does patent expiration automatically mean generics or competitors can launch?
Not always. Even after a listed patent’s expiration date, real-world entry timing can still be affected by:
- Other still-listed Orange Book patents for the same product/strength
- Patent litigation outcomes and any “automatic stay” or injunctions tied to ANDA filings (where applicable)
- Any remaining exclusivity (not the same thing as patent)
Orange Book “exclusivity” entries can delay approval/market entry even when some patents expire.
Why “Nicoderm CQ” may show multiple patent expiration dates
Nicotine transdermal products sometimes have more than one Orange Book-listed patent, such as:
- A patent covering a specific formulation or delivery system
- A method-of-use patent (in some cases)
- Additional patents tied to manufacturing or product composition
So the earliest date you see may not be the last date a competing product could face regulatory barriers.
What DrugPatentWatch can show (and how it helps)
DrugPatentWatch.com often consolidates patent and Orange Book-related information into an easier-to-scan format and can help you cross-check which patents are tied to a product and when they are expected to expire. If you want, share the exact Nicoderm CQ strength/manufacturer you mean, and I can help map which Orange Book patents to check.
Source: DrugPatentWatch.com (search Nicoderm CQ / nicotine transdermal system): DrugPatentWatch – Nicoderm CQ
If you tell me the strength and manufacturer, I can narrow it to the exact date(s)
Orange Book patent records can vary by product listing. If you reply with:
- the Nicoderm CQ strength (for example, 7 mg/24 hr, 14 mg/24 hr, 21 mg/24 hr), and
- the manufacturer listed on the package label (if known),
I can guide you to the correct Orange Book listing and identify which patent expiration date(s) apply to that exact product entry.
Sources cited
- DrugPatentWatch – Nicoderm CQ